Coherus Oncology (CHRS) Total Current Liabilities (2013 - 2026)

Coherus Oncology has disclosed Total Current Liabilities across 14 years of filings, most recently posting $132.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $132.3 million, down 48.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $132.3 million (down 48.11% YoY), and the FY2025 annual result was $140.4 million, down 50.39% from the prior year.
• Total Current Liabilities came in at $132.3 million for Q1 2026 at Coherus Oncology, down from $140.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $538.3 million in Q1 2024 to a low of $123.4 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $239.7 million (2023), against an average of $247.8 million.
• Across the five-year window, Total Current Liabilities surged 336.2% in 2024 and tumbled 52.62% in 2025, its largest moves.
• Coherus Oncology's Total Current Liabilities stood at $138.7 million in 2022, then jumped by 139.21% to $331.8 million in 2023, then dropped by 14.71% to $283.0 million in 2024, then plunged by 50.39% to $140.4 million in 2025, then dropped by 5.74% to $132.3 million in 2026.
• The last three Total Current Liabilities figures came in at $132.3 million (Q1 2026), $140.4 million (Q4 2025), and $372.3 million (Q3 2025), per Business Quant data.